Диссертация (1146697), страница 20
Текст из файла (страница 20)
– 13 (9). – P. 1431-38.118.Grehame R. The revised (Brighton, 1998) criteria for the diagnosisof benign joint hypermobility syndrome (BJHS) / R. Grehame, A. Bird,A. Child // J Rheumat. – 2000. – № 27(7). – P.1777-1779.119.Grover M. Assessment of bone mineral status in children withMarfan syndrome / M. Grover, N.
Brunetti-Pierri, J. Belmont [et al.] //Am J. of med. Gen. – 2012. – Part A. – 158 A. – P. 2221-2224.120.Heaney R.P. Distribution of calcium absorption in middle-agedwomen / R.P. Heaney, R.R. Recker // Am J ClinNutr. – 1986. – № 43 –Р. 299-305.135121.Heino T.J. Osteocytes inhibit osteoclastic bone resorption throughtransforming growth factor-beta: Enhancement by estrogen / T.J. Heino,T.A. Hentunen, H.K. Vaananen // J.
Cell Biochem. – 2002. – 85. – P.185-197.122.Jouanny P. (1995) Environmental and genetic factors affecting bonemass. Similarity of bone density among members of healthy families /P. Jouanny, F. Guillemin, C. Kuntz, C. Jeandel, J. Pourel // ArthritisRheum. – 1995. – 38. – P. 61-67.123.Kelly P.J. Interaction of genetic and environmental influences onpeak bone density / P.J. Kelly, J.A.
Eisman, P.N. Sambrook //Osteoporosis. Int. – 1990. – P. 56-60.124.Kimmel D.B. A comparison of iliac bone histomorphometric datain post-menopausal osteoporotic and normal subjects / D.B. Kimmel,R.R. Recker, J.C. Gallagher, A.S. Vaswani, J.F. Aloia // Bone Miner. –1990. – Nov. – 11 (2). – P.
217-35.125.Kingsley D.M. The TGF-beta superfamily: new members, newreceptors, and new genetic tests of function in different organisms / D.M.Kingsley // Genes Dev. – 1994. – Jan. 8 (2). – P. 133-46.126.Kleerekoper M. Biochemical studies in the evaluation andmanagement of osteoporosis: current status and future prospects / M.Kleerekoper, G.W. Edelson // Endocr. Pract. – 1996. - № 2. – Р. 13-19.127.Kohlmeier L. The bone mineral status of patients with Marfansyndrome / L. Kohlmeier, C. Gasner, L. Bachrach, R. Marcus // J BoneMiner Res. – 1995.
– 10. – P. 1550-5.128.Le Parc J.M. Bone mineral density in sixty adult patients withMarfan syndrome / J.M. Le Parc, P. Plantin, G. Jondeau, M. Goldschild[et al.] // Osteoporos Int. – 1999. – 10. – P. 475-9.129.Loeys B. Genotype and phenotype analysis of 171 patients referredfor molecular study of the fibrillin-1 gene FBN1 because of suspected136Marfan syndrome / B. Loeys, L.
Nuytinck, I. Delvaux, S. De Bie, A.B.De Paepe // Arch Intern Med. – 2001. – № 161 – Р. 2447-2454.130.Loeys B.L., Dietz H.C., Braverman A.C., et. al. The revised Ghentnosology for the Marfan syndrome // J. Med. Genet. – 2010. – Vol. 47. –№7. – Р. 476-485.131.Lu P.W. Volumetric bone mineral density in normal subjects, aged5–27 years / P.W. Lu, C.T. Cowell, S.A. Lloyd-Jones, J.N.
Briody,R.J. Howman-Giles // Clin Endocrinol Metab. – 1996. – 81. – P. 15861590.132.Malfait F. The genetic basis of the joint hypermobility syndromes /F. Malfait, A.J. Hakim, A. De Paepe, R. Grahame // Rheumatology. –2006. –133.№ 45. – Р. 502-507.Massic A. Screening for osteoporosis: comparison between dualenergy x-ray absorptiometry and broadband ultrasound attenuation in1000 perimenopausal women / A. Massic, D.M.
Reid, R.W. Porter //Osteoporosis Int. – 1993. – № 3. – P. 107-110.134.Matckovic V. Timing of peak bone mass in Caucasian females andits implication for the prevention of osteoporosis: inference from a crosssectional model / V. Matkovic, T. Jelic, G. Wardlaw [et al.] // J ClinInvest. – 1994. – 93.
– P. 799-808.135.Mikuni-Takagaki Y. Distinct responses of different populations ofbone cells to mechanical stress / Y. Mikuni-Takagaki, Y. Suzuki,T. Kawase, S. Saito // Endocrinology. – 1996. – 137. – P. 2028-2035.136.Mohammad K.S. Combined transforming growth factor β receptor Ikinase inhibitor and biphosphonates are additve to reduce breast cancerbone metastases / K.S. Mohammad, E.G. Stebbins, L. Kingsley, P.G.J.Fournier [et al.] // J Bone Miner Res.
– 2008. – 23. – P. 275.137.Mohammad K.S. Pharmacologic inhibition of the tgf-b type ireceptor kinase has anabolic and anti-catabolic effects on bone / K.S.137Mohammad, C.G. Chen, G. Balooch, E. Stebbins [et al.] // PLoS ONE. –2009. – № 4 (4) – e5275.138.Molyvda'Athanasopoulou E. Bone mineral density with dual photonabsorptiometry in four patients with osteogenesis imperfecta /E. Molyvda'Athanasopoulou, A. Siountas, A. Gotzamani'Psarrakou //Hell. J.
Nucl. Med. – 2001. – Vol.1. – P. 21-23.139.Moura B. Multidisciplinary Marfan syndrome clinic group. Bonemineral density in Marfan syndrome. A large case-control study / B.Moura, F. Tubach, M. Sulpice, C. Boileau [et al.] – Joint Bone Spine. –2006. –73 (6). – P. 733-5.140.National Osteoporosis Foundation // Washington. – 2010.http://www.nof.org/osteoporosis/diseasefacts.htm.141.Nelson B. What is osteopenia, and what should be done about it? /B. Nelson, M.D. Watts // Clevered Clinic. – 2006. – Vol.73. - №1. – P.29-32.142.Neptune E.R. Dysregulation of TGF-beta activation contributes topathogenesis in Marfan syndrome / E.R.
Neptune, P.A. Frischmeyer,D.E. Arking, L. Myers [et al.] // Nat. Genet. – 2003. – № 33 (3) – Р. 407411.143.Nistala H. Extracellular microfibrils control osteoblast-supportedosteoclastogenesis by restricting TGF-β stimulation of RANKLproduction / H. Nistala, S. Lee-Arteaga, S. Smaldone, G. Siciliano, F.Ramirez // J Biol Chem. – 2010. - № 2. – Р. 374-7.144.Official Positions and Pediatric Official Positions of theInternational Society for Clinical Densitometry 2007 [Electronicresource].–Modeofaccess:http://www.iscd.org/Visitors/positions/OfficialPositionsText.cfm145.Пасієшвілі Л.М. Особлив остікісткового обміну, метаболізмусполучної тканини і мінеральної щільності кісткової тканиниприокремих формах недиференційованої дисплазії сполучної138тканини/Л.М.Пасієшвілі,А.Б.Андруша//Кримськийтерапевтичний журнал.
– 2012. - №1. – С.78-81.146.Pyeritz R.E. The Marfan syndrome / R.E. Pyeritz // Annu. Rev.Med 2000. – Vol. 51 – P. 481-510.147.Peris P. Collagen type Iα1 gene polymorphism in idiopathicosteoporosis in men / P. Peris, L. Alvarez // Rheumatology. – 2000. – 39.– Р. 1222-5.148.Pocock N.A. Genetic determinants of bone mass in adults: a twinstudy // N.A.
Pocock, J.L. Hopper, P.N. Yeates, P.N. Sambrook, S.J.Ebert // Clin Invest. – 1987. – 80. – P. 706-710.149.Radonic Т. Losartan therapy in adult with Marfan syndrome: stadyprotocol of the multi-center randomized controlled COMPARE trial / Т.Radonic, P. de Witte, J.H. Baars, H.A. Zwinderman [et al.] // Journal:Trials – 2010. – vol.
11 – № 1 – Р. 3-5.150.RamachandranRamachandranM.M.JonesJonesD.D.2008.Osteogenesis[Medline]Imperfecta,retrievedfromhttp://emedicine.medscape.com/article/1256726-overview.151.Resolution WHA 51.18. Noncommunicable disease prevention andcontrol. In: Fifty-first World Health Assembly. – Geneva, 1998. – 27.2,3.152.Resolution WHA57.17.
Global Strategy on Diet, Physical Activityand Health. In: Fifty-seventhWorld Health Assembly, Geneva, 17–22May 2004. Resolutions and decisions, annexes. Geneva, World HealthOrganization.153.Riis В.J. Biochemical markers of bone turnover. II. Diagnosis,prophylaxis, and treatment of osteoporosis / В.J. Riis // Am J Med. –1993. – № 95 (5A). – Р.17-21.154.Sànchez-Riera L. Clinical and epidemiological research. Extendedreport: The global burden attributable to low bone mineral density /139L. Sànchez-Riera, E. Carnahan, T. Vos, L.
Veerman [et al.] // AnnRheum Dis. – 2014. – 73:9. – P. 1635-45.155.Saito M. Biochemical markers of bone turnover. New aspect. Bonecollagen metabolism: new biological markers for estimation of bonequality / M. Saito // Clin Calcium. – 2009. – Vol. 19. - № 8. – P. 1110-7.156.Schmierer B. TGFbeta-SMAD signal transduction: molecularspecificity and functional flexibility / B. Schmierer, C.S.
Hill // Nat. Rev.Mol. Cell Biol. – 2007. – 8 (12). – Р. 970-82.157.Shi Y. Mechanisms of TGF-beta signaling from cell membrane tothe nucleus / Y. Shi, J. Massagué // Cell. – 2003. – Jun. 13. – 113 (6). –Р.685-700.158.Sillence D.O. Genetic heterogeneity in osteogenesisimperfecta /D.O. Sillence, A. Senn, D.M. Danks // J. Med. Genet. – 1979. – Vol.
16.– P. 101-116.159.Singh K.K. TGF BR1 and TGF BR2 mutations in patients withfeatures of Marfan syndrome and Loeys–Dietz syndrome / K.K. Singh,K. Rommel, A. Mishra [et al.] // Hum Mutat. – 2006. – 27. – Р. 770–7.160.Subramaniam M. TIEG1 null mouse-derived osteoblasts aredefective in mineralization and in support of osteoclast differentiation invitro /M. Subramaniam, G. Gorny, S.A. Johnsen, D.G. Monroe [etal.] // Mol Cell Biol. – 2005.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
